RT Journal Article
SR Electronic
T1 MG-127 Residual disease monitoring in a retinoblastoma patient by pcr of a novel deletion breakpoint
JF Journal of Medical Genetics
JO J Med Genet
FD BMJ Publishing Group Ltd
SP A10
OP A10
DO 10.1136/jmedgenet-2015-103578.27
VO 52
IS Suppl 2
A1 Tim Corson
A1 Hilary Racher
A1 Bob Argiropoulos
A1 Helen Chan
A1 Renée Perrier
A1 Donco Matevski
A1 Diane Rushlow
A1 Furqan Shaikh
A1 Heather Trang
A1 Brenda Gallie
YR 2015
UL http://jmg.bmj.com/content/52/Suppl_2/A10.2.abstract
AB Background Allele-specific (AS)-PCR for known point mutations is a high-sensitivity method to monitor for minimal residual disease (MRD) in metastatic retinoblastoma. However, this approach is difficult to apply to large RB1 gene deletions.Objective We describe a novel, high sensitivity molecular assay for MRD monitoring of a large RB1 deletion.Method The proband’s retinoblastoma RB1 deletion was identified using quantitative multiplex (QM)-PCR. Array comparative genomic hybridization (aCGH) was used to map the boundaries of the tumour RB1 deletion. Inverse PCR was then applied to capture the unique deletion breakpoint, and AS primers were optimised for high sensitivity surveillance for MRD.Result Full RB1 gene testing revealed no mutation in blood of this patient. Using QM-PCR, we found one RB1 mutation in the retinoblastoma tumour (del P- >11). aCGH confirmed an ~238 kb hemizygous deletion extending centromeric from RB1. The precise deletion breakpoint was determined using inverse PCR to amplify from the known two-copy flanking sequence to identify a PCR product in tumour DNA that was absent from the patient’s blood DNA. AS primers based on the breakpoint detected a tumour-specific PCR product with a sensitivity of 1 in 1000 cells. The original bone marrow (BM) prior to therapy was strongly positive, but all subsequent BM, CSF, and cells harvested for stem cell transplant have been negative for the tumour-specific marker.Conclusion aCGH followed by inverse PCR provides a cost- and time-effective way to map QM-PCR detected RB1 breakpoints for high sensitivity molecular surveillance for MRD.